Back to results
US 11,078,275 B2Granted
Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
AssigneeInnate Pharma
InventorsCecile Bonnafous, Helene Sicard, Renaud Buffet
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
Claims12
A method of treating an enteropathy-associated T cell lymphoma (EATL), comprising administering to an individual suffering from said EATL a therapeutically active amount of an antibody that binds a KIR3DL2 polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 and that further:
- i) directs ADCC toward a KIR3DL2-expressing cell, or ii) delivers a cytotoxic agent to a KIR3DL2-expressing cell.
Dependencies are inferred from the claim text.